Choroid Plexus plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The choroid plexus (CP) is a highly specialized structure located within the brain ventricles that serves as the primary site for cerebrospinal fluid (CSF) production. This delicate, villous tissue represents a critical interface between the blood and CSF compartments, forming the blood-CSF barrier (BCSFB). Beyond its traditional role in CSF synthesis, the choroid plexus has emerged as a key player in brain homeostasis, neuroimmune regulation, and neurodegenerative disease pathogenesis. The CP is increasingly recognized as a potential therapeutic target for conditions including Alzheimer's disease (AD), Parkinson's disease (PD), normal pressure hydrocephalus (NPH), and multiple sclerosis (MS).
¶ Location and Structure
The choroid plexus is found in all four ventricles of the brain:
Lateral Ventricles:
- Body of lateral ventricle (choroidal fissure)
- Temporal horn (inferior horn)
- Produces majority of CSF (~70-80%)
Third Ventricle:
- Roof of the third ventricle
- Smaller contribution to total CSF production
Fourth Ventricle:
- Roof and lateral recesses
-重要 outlet for CSF to subarachnoid space
The choroid plexus comprises several distinct cell types organized into a highly specialized epithelium:
Choroid Plexus Epithelial Cells (CPECs):
- Cuboidal to columnar epithelium (15-25 μm height)
- Apical microvilli and basolateral infoldings
- Tight junctions between adjacent cells (claudin-1, claudin-2, occludin)
- Highly developed endoplasmic reticulum and mitochondria
- Primary site of CSF secretion
Stromal Cells:
- Fibroblast-like cells in the core
- Produce extracellular matrix components
- Support blood vessels
- Immunomodulatory functions
Endothelial Cells:
- Continuous capillaries with tight junctions
- Higher permeability than brain endothelial cells
- Form the inner blood-stroma barrier
- Express various transport systems
Immune Cells:
- Resident macrophages (CD68+)
- Dendritic cells
- T lymphocytes (minor population)
- Surveillance function
The BCSFB is formed by the choroid plexus epithelium and represents a distinct interface from the blood-brain barrier (BBB):
Tight Junction Proteins:
- Claudin-1, Claudin-2, Claudin-3
- Occludin
- ZO-1 (zonula occludens-1)
- Tricellulin
Transport Mechanisms:
- Ion transporters (Na+/K+-ATPase, NKCC1)
- Glucose transporters (GLUT1)
- Amino acid transporters
- Organic anion transporters
- Receptor-mediated transcytosis
CSF production is an active, energy-dependent process:
Primary Active Transport:
- Na+/K+-ATPase on apical membrane
- Creates sodium gradient driving fluid secretion
- Accounts for ~60% of CSF production
Secondary Active Transport:
- NKCC1 (Na+-K+-2Cl- cotransporter)
- Cl- channels (CFTR, Bestrophin-1)
- K+ channels
Water Transport:
- Aquaporin-1 (AQP1) on apical membrane
- Osmotic gradient-driven water flow
- AQP4 in supporting cells
¶ Rate and Composition
Production Rate:
- Normal: 400-600 mL/day
- Turnover: 3-4 times daily
- Pressure-dependent regulation
CSF Composition:
- Sodium: 135-150 mM
- Potassium: 2.5-3.5 mM
- Calcium: 1.1-1.3 mM
- Magnesium: 1.5-2.0 mM
- Glucose: 50-80 mg/dL (60% of blood glucose)
- Protein: 15-45 mg/dL
- Cells: <5 lymphocytes/μL
¶ Brain Clearance and the Glymphatic System
The choroid plexus plays a crucial role in brain waste clearance:
Glymphatic Pathway:
- CSF flows from periarterial spaces into brain parenchyma
- Aquaporin-4 (AQP4) on astrocyte end-feet facilitates bulk flow
- Interstitial fluid drains along perivenous routes
- CSF exits via arachnoid granulations and nasal lymphatics
CP Contributions:
- Provides CSF for the glymphatic system
- May directly clear solutes from brain interstitial fluid
- Maintains CSF turnover for waste removal
- Clearances: amyloid-β, tau, lactate, neurotransmitters
The choroid plexus serves as a neuroimmune interface:
Immune Surveillance:
- Resident immune cells monitor CSF
- Entry point for peripheral immune cells
- Cytokine production and signaling
Neuroinflammation Modulation:
- Produces anti-inflammatory cytokines (IL-10, TGF-β)
- Expresses pattern recognition receptors
- Can mount innate immune responses
Leukocyte Trafficking:
- Regulated by adhesion molecules (VCAM-1, ICAM-1)
- Chemokine gradients guide cell migration
- CNS immune privilege maintained
¶ Transport and Signaling
Nutrient Delivery:
- Transfers essential molecules to CNS
- Vitamin transporters
- Hormone receptors (insulin, leptin)
- Thyroid hormone transport
CNS-to-Blood Signaling:
- Releases neuroendocrine factors
- Feedback to hypothalamic-pituitary axis
- Circadian rhythm coordination
The choroid plexus is intimately involved in AD pathogenesis:
CSF Dynamics:
- Altered CSF production rates
- Impaired CSF circulation
- Reduced glymphatic clearance
Aβ Clearance:
- Reduced Aβ42 transport from CSF to blood
- Decreased LRP-1 expression on CP
- Accumulation in brain parenchyma
Biomarkers:
- CSF Aβ42/Aβ40 ratio reduced
- Total tau and phosphorylated tau elevated
- Reflects brain amyloid and tau pathology
Choroid Plexus Atrophy:
- Reduced CP volume with age
- Accelerated atrophy in AD
- Correlates with cognitive decline
Pathological Mechanisms:
- Chronic inflammation damages CP epithelium
- Oxidative stress impairs function
- Mitochondrial dysfunction
- Cellular senescence
CSF Composition:
- α-Synuclein in CSF
- Reduced DJ-1 protein
- Altered tau levels
Clearance Dysfunction:
- Glymphatic system impaired
- CP function reduced
- Waste accumulation in brain
Clinical Correlations:
- CP morphology correlates with disease duration
- Autonomic dysfunction linked to CP health
The CP is central to NPH pathophysiology:
CSF Dynamics:
- Impaired CSF absorption
- Altered pressure relationships
- Ventriculomegaly with normal pressure
CP Pathology:
- Choroid plexus calcification increased
- Epithelial degeneration
- Reduced CSF production in some cases
Treatment Implications:
- CSF drainage improves symptoms
- Ventriculoperitoneal shunting
- CP function as therapeutic target
Immune Interface:
- Entry point for immune cells
- BBB disruption mirrored at BCSFB
- Cytokine-mediated damage
CSF Findings:
- Oligoclonal bands
- Elevated IgG index
- Inflammatory markers
¶ ALS and Other Neurodegenerative Diseases
Choroid Plexus Involvement:
- CSF biomarker alterations
- Neurofilament light chain elevated
- Altered protein profiles
Therapeutic Implications:
- Drug delivery target
- BCSFB as entry point for therapies
- Gene therapy approaches
The choroid plexus undergoes significant age-related changes:
Structural:
- Epithelial cell atrophy
- Decreased microvilli
- Increased lysosomal lipofuscin
- Calcification (choroid plexus stones)
Functional:
- Reduced CSF production (~20% decrease)
- Impaired transport
- Reduced clearance capacity
- Increased permeability
Molecular:
- Cellular senescence markers
- Oxidative damage accumulation
- Mitochondrial dysfunction
- Telomere shortening
Implications:
- Cognitive decline risk
- Neurodegeneration susceptibility
- Glymphatic clearance reduction
Cell Cultures:
- Primary choroid plexus epithelial cells
- Immortalized cell lines (Z310, CPC-β)
- Polarized monolayer systems
Organoids:
- Brain organoids with CP-like structures
- Patient-derived iPSC models
Animal Models:
- Rodent choroid plexus
- Transgenic models (APP/PS1, α-synuclein)
- Aging models
Experimental Approaches:
- CSF infusion studies
- Tracer injections
- Live imaging
- MRI: CP volume, morphology
- Dynamic contrast-enhanced MRI: permeability
- PET: metabolic activity
- Two-photon microscopy: real-time imaging
- CSF collection and analysis
- In situ brain perfusion
- Ussing chamber measurements
- Transport kinetics
- Transcriptomics
- Proteomics
- Metabolomics
- Single-cell sequencing
CP as Target:
- Intrathecal drug administration
- Intranasal delivery (olfactory route)
- Focused ultrasound opening BCSFB
- Nanoparticle delivery systems
Transport Exploitation:
- Receptor-mediated transcytosis
- Trojan horse approaches
- Nutrient transporters
- Stem cell therapy
- Tissue engineering
- Gene therapy
- Protein replacement
CP-Derived Biomarkers:
- CSF protein profiles
- CP-specific molecules
- Imaging markers
Clinical Applications:
- Early diagnosis
- Disease progression
- Treatment response
Choroid Plexus plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Choroid Plexus has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Balusu et al., Choroid plexus and Alzheimer's disease (2023)
- Damkier et al., Blood-CSF barrier function (2022)
- Ghai et al., Choroid plexus in neurodegeneration (2024)
- Iliff et al., Glymphatic system and brain clearance (2023)
- Johansson, Choroid plexus and CSF in brain homeostasis (2023)
- Khasawneh et al., Choroid plexus aging (2024)
- Lun et al., CSF production mechanisms (2022)
- Marsh et al., Choroid plexus as therapeutic target (2023)
- Matsumoto et al., Aβ clearance via choroid plexus (2024)
- Redzic, Molecular biology of the choroid plexus (2023)
- Serot et al., Choroid plexus and aging (2022)
- Strazielle & Ghersi-Egea, Choroid plexus in drug delivery (2023)
- Symms et al., MRI of choroid plexus in disease (2024)
- Wolburg & Paulus, Choroid plexus epithelium tight junctions (2022)
- Zheng et al., Choroid plexus organoids (2024)